

1. Abdalla Y, Luo M, Mäkilä E, Day BW, Voelcker NH and Tong WY. Effectiveness of porous silicon nanoparticle treatment at inhibiting the migration of a heterogeneous glioma cell population. *Journal of Nanobiotechnology*. 2021, 19(1), 1-16. IF = 10.435
2. Alhalabi OT, Fletcher MNC, Baumgartner U, Hielscher T, Kessler T, Wittmann E, Schlue S, Rahman S, Hai L, Hansen-Palmus L, Puccio L, Nakano I, Herold-Mende C, Wick W, Sahm F, Day BW, Phillips E, Goidts V. A novel patient stratification strategy to enhance the therapeutic efficacy of dasatinib in glioblastoma. *Neuro-Oncology*. Accepted July 2021. IF = 12.3
3. Baumgartner U, D'Souza RCJ, Offenhäuser C, Akgül S and Day BW. Future Perspectives: A Review of Therapeutic Advances in Recurrent Glioblastoma. *Journal of Cancer Sciences and Clinical Therapeutics*. 2021 July 1, 5, 286-308. IF = 3.2
4. Müller Bark J, Kulasinghe A, Hartel G, Leo P, Warkiani ME, Jeffree RL, Chua B, Day BW and Punyadeera C. Isolation of Circulating Tumour Cells in Patients With Glioblastoma Using Spiral Microfluidic Technology—A Pilot Study. *Frontiers In Oncology*. 2021 June 3. IF = 4.848
5. Gan H, Cher L, Inglis PL, Lwin Z, Lau E, Wichmann C, Ackermann U, McDonald A, Gunjur A, Coombs N, Remen K, Guo N, Lee ST, Gong S, Palmer J, Pathmaraj K, O'Keefe G, Scott F, Day BW, Boyd AW, Thomas P, Ahmed O, Chappell D, Durrant C and Scott A. Phase I safety and bioimaging trial of ifabotuzumab in patients with glioblastoma. *Journal of Nuclear Medicine*. 2021 May 1, 62(1), 104. IF = 10.057
6. Lenin S, Ponthier E, Scheer KG, Yeo ECF, Tea MN, Ebert LM, Mansilla MO, Poonnoose S, Baumgartner U, Day BW, Ormsby RJ, Pitson SM and Gomez GA. A Drug Screening Pipeline Using 2D and 3D Patient-Derived In Vitro Models for Pre-Clinical Analysis of Therapy Response in Glioblastoma. *International Journal of Molecular Sciences*. 2021 April 21, 22(9), 4322. IF = 4.556
7. Recasens A, Humphrey SJ, Ellis M, Hoque M, Abbassi RH, Chen B, Longworth M, Needham EJ, James DE, Johns TJ, Day BW, Kassiou M, Yang P, Munoz L. Global phosphoproteomics reveals DYRK1A regulates CDK1 activity in glioblastoma cells. *Cell Death Discovery*. 2021 April 16, 7(1), 1-16. IF = 3.962
8. Wael Y, Abdalla BM, Luo M, Mäkilä E, Day BW, Voelcker N and Tong WY. Effectiveness of porous silicon nanoparticle treatment at inhibiting the migration of a heterogeneous glioma cell population. *Journal of Nanobiotechnology*. 2021 February 26, 19(1), 1-16. IF = 6.937
9. Chen B, McCuaig-Walton D, Tan S, Montgomery AP, Day BW, Kassiou M, Munoz L, Recasens A. DYRK1A Negatively Regulates CDK5-SOX2 Pathway and Self-Renewal of Glioblastoma Stem Cells. *International Journal of Molecular Sciences*. 2021 January 1, 22(8), 4011. IF = 4.556

10. Hoque M, Wong SW, Recasens A, Abbassi R, Nguyen N, Zhang D, Stashko MA, Wang X, Frye S, Day BW, Baell J and Munoz L. MerTK activity is not necessary for the proliferation of glioblastoma stem cells. *Biochemical Pharmacology*. 2021 January 4. IF = 4.960
11. Ebert EM, Yu W, Toubia J, Gargett T, Tea MN, Ebert BW, Bardy C, van den Hurk M, Bonder CS, Manavis J, Ensbey KS, Mansilla MO, Scheer K, Perrin SL, Ormsby RJ, Poonnoose S, Koszyca B, Pitson SM, Day BW, Gomez GA and Brown MP. Endothelial, pericyte and tumour cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapy. *Clinical & Translational Immunology*. 2020 October 14. IF = 6.464
12. D'Souza RCJ, Offenhauser C, Straube J, Baumgartner U, Kordowski A, Li Y, Stringer BW, Alexander H, Lwin Z, Inglis P, Jeffree RL, Johns T, Boyd AW, Day BW. Q-Cell Glioblastoma Resource: Proteomics Analysis Reveals Unique Cell-States are Maintained in 3D Culture. *Cells*. (Accepted Jan 2020). IF = 4.33
13. Stringer BW*, Day BW*, D'Souza CJ, Jamieson PR, Ensbey KS, Bruce ZC, Lim YC, Goasdoué K, Offenhauser C, Akgul S, Allan S, Robertson T, Lucas P, Tolleson G, Campbell S, Winter C, Do H, Dobrovic A, Inglis P, Jeffree RL, Johns TG, Boyd AW. A reference collection of patient-derived cell line and xenograft models of proneural, classical and mesenchymal glioblastoma. *Scientific Reports*. 2019 March 20. 9 (4902). doi: <https://doi.org/10.1038/s41598-019-41277-z> IF = 5.578
14. Day BW, Stringer BW, Wilson J, Jeffree RL, Jamieson PR, Ensbey KS, Bruce ZC, Inglis P, Allan S, Winter C, Tolleson G, Campbell S, Lucas P, Findlay W, Kadrian D, Johnson D, Robertson T, Johns TG, Bartlett PF, Osborne GW, Boyd AW. Glioma surgical aspirate: a viable source of tumor tissue for experimental research. *Cancers (Basel)*. 2013 Apr 3;5(2):357-71. doi: <https://www.mdpi.com/2072-6694/5/2/357> IF = 6.102
15. Brighi C, Reid L, Genovesi LA, Kojic M, Millar A, Bruce Z, White AL, Day BW, Rose S, Whittaker AK and Puttick S. Comparative study of preclinical mouse models of high-grade glioma for nanomedicine research: the importance of reproducing blood-brain barrier heterogeneity. *Theranostics*. 2020 May 15, 10(14), 6361-6371. IF = 8.063
16. O'Brien EA, Ensbey KS, Day BW, Baldock PA, Barry G. Direct evidence for transport of RNA from the mouse brain to the germline and offspring. *BMC Biology*. 2020 April 30, 18(1), 45. IF = 6.723
17. Phoa AF, Recasens A, Gurgis FMS, Betts TA, Menezes SV, Chau D, Nordfors K, Haapasalo H, Johns TG, Stringer BW, Day BW, Buckland ME, Lalaoui N and Munoz L. MK2 Inhibition induces p53-dependent Senescence in Glioblastoma Cells. *Cancers*. Accepted March 9, 2020. IF = 6.102

18. Brighi C, Reid L, White AL, Genovesi LA, Kojic M, Millar A, Bruce Z, Day BW, Rose S, Whittacker AK and Puttick S. MR-guided focused ultrasound increases antibody delivery to non-enhancing high-grade glioma. *Neuro-Oncology Advances*. 2020 March 5. IF = 10.091
19. Khanna A, Thoms J, Stringer BW, Chung S, Ensbey K, Jue TR, Jahan Z, Subramanian S, Anande G, Shen H, Unnikrishnan A, McDonald K, Day BW and Pimanda J. Constitutive CHK1 expression drives a pSTAT3-CIP2A circuit that promotes glioblastoma cell survival and growth. *Molecular Cancer Research*. Accepted February 2, 2020. IF = 4.484
20. Lim YC, Ensbey KS, Offenhäuser C, D'Souza RCJ, Cullen JK, Stringer BW, Quek H, Bruce ZC, Kijas A, Cianfanelli V, Mahboubi B, Smith F, Jeffree RL, Wiesmüller L, Wiegmanns AP, Bain A, Lombard FJ, Roberts TL, Khanna KK, Lavin MF, Baek K, Hamerlik P, Johns TG, Coster MJ, Boyd AW and Day BW. Simultaneous Targeting of DNA Replication and Homologous Recombination in Glioblastoma with a Polyether Ionophore. *Neuro-Oncology*. 2020 Feb 20. doi: 10.1093/neuonc/noz159. IF = 10.091
21. Gedye C, Sachchithanathan M, Leonard R, Jeffree RL, Buckland ME, Ziegler DS, Graeber MB, Day BW, McDonald KL, BCBA Consortium and Nowak AK. Driving innovation through collaboration: development of clinical annotation datasets for brain cancer biobanking. *Neuro-Oncology Practice*. 2020 January 31, 7(1), 31-37. IF = 10.091
22. Chen KS, Bridges CR, Lynton Z, Lim JWC, Stringer BW, Rajagopal R, Wong K, Ganesan D, Ariffin H, Day BW, Richards LJ and Bunt J. Transcription factors NFIA and NFIB induce cellular differentiation in high-grade astrocytoma. *Journal of Neuro-Oncology*. 2020 Jan 1,146(1), 41-53. IF = 3.129
23. Day BW, Lathia JD, Bruce ZC, D'Souza RCJ, Baumgartner U, Ensbey KS, Lim YC, Stringer BW, Akgul S, Offenhauser C, Li Y, Jamieson PR, Smith FM, Jurd CLR, Robertson T, Inglis PL, Lwin Z, Jeffree R, Johns TG, Bhat KPL, Rich JN, Campbell KP, and Boyd AW. The Dystroglycan Receptor Maintains Glioma Stem Cells in the Vascular Niche. *Acta Neuropathologica*, 2019 Dec, 138(6), 1033-1052. IF = 18.1
24. Bark J, Kulasinghe A, Chua B, Day BW and Punyadeera C. Circulating biomarkers in patients with glioblastoma. *British Journal of Cancer*. 2019 Oct 31, 1-11. IF = 5.922
25. Abbassi RH, Recasens A, Indurthi DC, Johns TG, Stringer BW, Day BW, Munoz L. Lower tubulin expression in glioblastoma stem cells attenuates efficacy of microtubule-targeting agents. *ACS Pharmacology & Translational Science*. 2019 July 30. IF = 4.325

26. Hallal S, Mallawaarachy DM, Wei H, Ebrahimkhani S, Stringer BW, Day BW, Boyd AW, Guillemin GJ, Buckland ME, Kaufman KL. Extracellular vesicles released by glioblastoma cells stimulate normal astrocytes to acquire a tumor-supportive phenotype via p53 and MYC signaling pathways. *Molecular Neurobiology*. 2019 June 1, 56(6), 4566-4581. IF = 5.076
27. Akgul S*, Patch AM*, D'Souza RCJ, Mukhopadhyay P, Nones K, Kempe S, Kazakoff SH, Jeffree RL, Stringer BW, Pearson JV, Waddell N and Day BW. Intratumoural Heterogeneity Underlies Distinct Therapy Responses and Treatment Resistance in Glioblastoma. *Cancers*. 2019 February 6, 11(2), 190. IF = 6.126
28. Neubauer HA, Tea MN, Zebol JR, Gliddon BL, Stefanidis C, Moretti PAB, Pitman MR, Costabile M, Kular J, Stringer BW, Day BW, Samuel MS, Bonder CS, Powell JA, Pitson SM. Cytoplasmic dynein regulates the subcellular localization of sphingosine kinase 2 to elicit tumor-suppressive functions in glioblastoma. *Oncogene*. 2019 February, 38(8), 1151. IF = 8.459
29. Mitchell CB, Black B, Sun F, Chrzanowski W, Cooper-White J, Maisonneuve B, Stringer BW, Day BW, Biro M and O'Neill GM. Tropomyosin Tpm 2.1 loss induces glioblastoma spreading in soft brain-like environments. *Journal of Neuro-Oncology*. 2019 January 1, 141(2), 303-313. IF = 3.129
30. Chen KS, Bunt J, Bridges CR, Lynton Z, Lim WCJ, Stringer BW, Rajagopal R, Wong KT, Ganesan D, Ariffin H, Day BW and Richards LJ. Transcription factors NFIA and NFIB induce cellular differentiation in high-grade astrocytoma. *bioRxiv*. 2019 January 1.
31. Offenhäuser C, Al-Ejeh F, Puttick S, Ensbey KS, Bruce ZC, Jamieson PR, Smith FM, Stringer BW, Carrington B, Fuchs AV, Bell CA, Jeffree R, Rose S, Thurecht KJ, Boyd AW, Day BW. EphA3 Pay-Loaded Antibody Therapeutics for the Treatment of Glioblastoma. *Cancers*. 2018 Dec 17;10(12). pii: E519. IF = 6.126
32. Hoque M, Abbassi RH, Froio D, Man J, Johns TG, Stringer BW, Day BW, Pajic M, Kassiou M, Munoz L. Changes in cell morphology guide identification of tubulin as the off-target for protein kinase inhibitors. *Pharmacological Research*. 2018 Jun 23, 134, 166-178. IF = 4.408
33. Lim YC, Quek H, Offenhäuser C, Fazry S, Boyd A, Lavin M, Roberts T, Day BW. ATM Inhibition Prevents Interleukin-6 from Contributing to the Proliferation of Glioma Initiating Cells after Ionizing Radiation. *Journal of Neuro-Oncology*. 2018 July, 138(3), 509-518. IF = 3.060
34. Whittaker S, Madani D, Joshi S, Chung SA, Johns T, Day BW, Khasraw M, McDonald KL. Combination of Palbociclib and Radiotherapy for glioblastoma. *Cell Death Discovery*. 2017 Jul 3;3:17033. IF = 5.5

35. Greenall SA, Lim YC, Mitchell CB, Ensbey KS, Stringer BW, Wilding AL, O'Neill GM, McDonald KL, Gough DJ, Day BW, Johns TG. Cyclin-Dependent Kinase 7 Is a Therapeutic Target in High-Grade Glioma. *Oncogenesis*. 2017 May 15;6(5):e336. IF = 4.722
36. Gilabert-Oriol R, Furness SGB, Stringer BW, Weng A, Fuchs H, Day BW, Kourakis A, Boyd AW, Hare DL, Thakur M, Johns TG, Wookey PJ. Dianthin-30 or gelonin versus monomethyl auristatin E, each configured with an anti-calcitonin receptor antibody, are differentially potent in vitro in high grade glioma cell lines derived from glioblastoma. *Cancer Immunology*. 2017 Sep;66(9):1217-1228. IF = 9.188
37. Zhou Q, Phoa AF, Abbassi RH, Hoque M, Reekie TA, Font JS, Ryan RM, Stringer BW, Day BW, Johns TG, Munoz L, Kassiou M. Structural optimization and pharmacological evaluation of inhibitors targeting dual-specificity tyrosine phosphorylation-regulated kinases (DYRK) and CDC-like kinases (CLK) in glioblastoma. *Journal of Medicinal Chemistry*. 2017 Mar 9;60(5):2052-2070. IF = 6.259
38. Tivnan A, Heilinger T, Ramsey JM, O'Connor G, Pokorny JL, Sarkaria JN, Stringer BW, Day BW, Boyd AW, Kim EL, Lode HN, Cryan SA, Prehn JH. Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells. *Oncotarget*. 2017 Mar 7;8(10):16605-16620. IF = 6.368
39. Döbber A, Phoa AF, Abbassi RH, Stringer BW, Day BW, Johns TG, Abadleh M, Peifer C, Munoz L. Development and biological evaluation of a photoactivatable small molecule microtubule-targeting agent. *ACS Medicinal Chemistry Letters*. 2017 Mar 15;8(4):395-400. IF = 3.794
40. Stringer BW, Bunt J, Day BW, Barry G, Jamieson P, Ensbey K, Bruce Z, Goasdoue K, Vidal H, Charmsaz S, Smith F, Cooper L, Piper M, Boyd AW, Richards L. Nuclear Factor One B (NFIB) encodes a subtype-specific tumour suppressor in glioblastoma. *Oncotarget* 2016 May 17;7(20):29306-20. IF = 6.368
41. Grundy TJ, De Leon E, Griffin KR, Stringer BW, Day BW, Fabry B, Cooper-White, J O'Neill GM. Differential response of patient-derived primary glioblastoma cells to environmental stiffness. *Scientific Reports*. 2016 Mar 21;6:23353. IF = 5.578
42. Zakaria Z, Tivnan A, Flanagan L, Murray D, Salvucci M, Stringer B, Day BW, Boyd A, Koegel D, Rehm M, O'Brien D, Byrne A, Prehn J. Patient-derived glioblastoma cells show significant heterogeneity in treatment responses to the inhibitor-of-apoptosis-protein (IAP) antagonist Birinapant. *British Journal of Cancer*. 2016 Jan 19;114(2):188-98. IF = 4.836.

43. Phoa AF, Browne S, Gurgis FM, Akerfeldt MC, Doebber A, Renn C, Peifer C, Stringer BW, Day BW, Wong C, Chircop M, Johns TG, Kassiou M, Munoz L. Pharmacology of novel small-molecule tubulin inhibitors in glioblastoma cells with enhanced EGFR signalling. *Biochemical Pharmacology*. 2015 Dec 15;98(4):587-601. IF = 5.009
44. Puttick S, Stringer BW, Day BW, Bruce ZC, Ensbey KS, Mardon K, Cowin GJ, Thurecht KJ, Whittaker AK, Fay M, Boyd AW, Rose S. EphA2 as a Diagnostic Imaging Target in Glioblastoma: A PET/MRI Study. *Molecular Imaging*. 2015 Jul 1;14:8-28. IF = 3.408
45. Rundle-Thiele D, Day BW, Stringer BW, Fay M, Martin J, Jeffrey R, Thomas P, Bell C, Salvado O, Gal Y, Coulthard A, Crozier S, & Rose S. Using the apparent diffusion coefficient to identifying MGMT promoter methylation status early in glioblastoma: importance of analytical method. *Journal of Medical Radiation Sciences*. 2015 Apr 62: 92–98. IF not available.
46. Hosein AN, Lim YC, Day BW, Stringer B, Rose S, Head R, Cosgrove L, Sminia P, Fay, M, Martin JH. The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells. *Journal of Neuro-Oncology*. 2015 Apr;122(2):263-71. IF = 2.78
47. Rahman M, Reyner K, Deleyrolle L, Millette S, Azari H, Day BW, Stringer BW, Boyd AW, Johns TG, Blot V, Duggal R, Reynolds B. Neurosphere and adherent culture conditions are equivalent for malignant glioma stem cell lines. *Anatomy and Cell Biology*. 2015, Mar;48(1):25-35. IF not available.
48. Lim YC, Roberts TL, Day BW, Stringer BW, Kozlov S, Fazry S, Bruce ZC, Ensbey KS, Walker DG, Boyd AW, Lavin MF. Increased sensitivity to ionizing radiation by targeting the homologous recombination pathway in glioma initiating cells. *Molecular Oncology*. 2014 Dec;8(8):1603-15. IF = 6.70
49. Day BW, Stringer BW and Boyd AW. Eph Receptors as Therapeutic Targets in Glioblastoma. *British Journal of Cancer*. 2014 Sept 23;111(7):1255-61. IF = 5.082
50. Tivnan A, Zhao J, Johns TG, Day BW, Stringer B, Boyd A, Tiwari S, Giles KM, Teo C, McDonald KL. The tumour suppressor microRNA, miR-124a, is regulated by epigenetic silencing and by the transcriptional factor, REST in glioblastoma. *Tumour Biology*. 2014 Feb;35(2):1459-65. IF = 2.518
51. Day BW, Stringer BW, Al-Ejeh F, Ting MJ, Wilson J, Ensbey KS, Jamieson PR, Bruce ZC, Lim YC, Offenhäuser C, Charmsaz S, Cooper LT, Ellacott JK, Harding A, Leveque L, Inglis P, Allan S, Walker DG, Lackmann M, Osborne G, Khanna KK, Reynolds BA, Lickliter JD, Boyd AW. EphA3 Maintains Tumourigenicity and is a Therapeutic Target in Glioblastoma Multiforme. *Cancer Cell*. 2013 Feb 11;23(2):238-48. IF= 26.566